- Kaiser Permanente names SVP, Fresno service area manager
- Nebraska hospital CEO resigns amid allegations of $38K in improper spending
- Northwell’s direct contracting business wants to ‘link up’ with other health systems
- PDS Health among 1st to deploy Epic-integrated AI platform
- CommonSpirit’s 5 targets for judging payer prior auth reform — and its Humana milestone
- LifeBridge names division president
- Private equity struggles in healthcare amid mounting pressures: 5 notes for dentistry
- Who’s actually winning the fight for ASC ownership?
- Why some ASCs are buying their own anesthesia groups
- Hospital Sisters Health System names chief technology officer
- Top Medicare Advantage plans for member satisfaction in 2026: JD Power
- How a 12-hospital system saved millions with an inventory overhaul
- Corporate medicine is burning out 90% of employed physicians: 10 survey findings
- HCA Florida hospital names assistant CFO
- GE HealthCare taps new CFO
- 6-property outpatient portfolio acquired
- Patients deserve every evidence-based option for mental healthcare
- 10 anesthesia controversies in 2026
- The $314K cost of employing a physician
- Who’s driving physician M&A in 2026? 5 deals to know
- 5 ways insurers are undercutting anesthesia payments: ASA
- Prior GLP-1 use doesn’t affect bariatric surgery results: 6 things to know
- Statement on Regulation Crypto Assets: Fit-for-purpose Exemptions for Crypto Market Innovation
- Filling the Regulatory Tank: Regulation Crypto Assets Proposing Release
- Statement on Regulation Crypto Assets
- Dental therapy program enrollment up 533% in 5 years
- Dental assisting program enrollment down 5.2% in 5 years
- Dental hygiene program enrollment up 15% in 5 years
- Surgery Partners ditches its $200M M&A target in favor of de novo growth: 5 things to know
- The dental specialties DSOs will prioritize next
- Statement on Commencement of Appointment Process for Public Company Accounting Oversight Board Seat
- Dental school enrollment in the 10 states with the most dental shortage areas
- How To Protect Yourself During Wildfire Season
- Ballmer Institute lands $125M to expand child behavioral health training nationwide
- Judge weighs whether man charged with killing dentist can act as own attorney
- FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices
- Included Health to offer Carrum specialty care for alternative plan members
- 52 behavioral health executive moves to know
- Hospital performance improves in June, but lags 2025
- University of Toledo gets nearly $2M to support behavioral health workforce
- CTA reporting requirements eliminated for most dental practices: 5 things to know
- National Alliance on Mental Illness names chief medical officer
- Pennsylvania opens 24/7 behavioral health crisis center
- Cyber criminals target DSOs, dental groups: 3 updates
- OpenAI boosts mental health safeguards for teens
- UnitedHealthcare expands behavioral coaching to 13 million members
- Kindergarten Vaccine Exemptions Hit Record High, New CDC Data Shows
- Loneliness Is A Health Crisis, But Doctors Alone Can't Cure It, Analysis Argues
- Ousted OHSU Healthcare CEO files lawsuit alleging wrongful termination, discrimination
- JD Power: Member satisfaction with Medicare Advantage plans continues to slide
- AMA applauds updated CMS prior authorization reporting guidance
- Constipation In Space: A New Study Provides Answers
- Social Media Beauty Trends May Up Teens' Exposure To Hormone-Disrupting Chemicals
- HIPAA-compliant marketing platform Ours Privacy lands $15M amid growing pixel concerns
- Pharma commercialization partner Valeris brings in new strategy chief
- Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global test
- CSL shares up 17% as immunoglobulin boost points to signs of recovery
- R1 acquiring Humata Health to bolster AI-powered prior authorizations
- Revance hires Janelle Wichmann as chief marketing officer of skincare unit
- CMI adopts orphan drug field with dedicated center of excellence
- Waist Size Is Accurate Way To Gauge Unhealthy Excess Weight, Study Says
- Panel Offers First Guidelines For Using E-Cigarettes To Help Smokers Quit
- Celcuity keeps cool amid questions about Revtorpyk launch timing
- Newsom Promotes Affordable Insulin, But California's Generic Label Off To A Slow Start
- What Geriatric Emergency Departments Do Differently
- Drive for Nuclear Power Boosts Uranium Industry — And Tribal Health Concerns in Southwest
- Rural primary care company Hopscotch clinches $53M to expand beyond NC
- Eurofins expands operations to meet growing high-potency API demand
- 24 new behavioral health projects to know
- Four health systems, including Ochsner and Denver Health, go live with Epic's real-time prior authorization checks
- 8 new psychiatric residency programs to know
- DocGo agrees to acquire virtual care provider Hicuity Health, assumes $52M debt
- Papa, eternalHealth expand partnership around Plus platform
- Happy Health secures $75M to expand AI-powered care in the home starting with sleep apnea
- As healthcare costs weigh on patients, states could play a bigger role, report finds
- Jalapeño Recalls Keep Growing As Salmonella Outbreak Investigation Continues
- Music Streaming Linked To Rise In Traffic Deaths
- EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
- Quanovate takes back marketing claims for Mira fertility wand after P&G challenge
- Sanofi to lay off 229 Blueprint Medicines staffers, close Cambridge offices following acquisition
- Whoop expands Advanced Labs to non-members, adds Grail’s multi-cancer detection test to lineup
- Quartz Countertop Workers Are Falling Prey To Lung Disease
- Kaiser Permanente notches 4.6% Q2 operating margin, $5.3B net income
- Epic faces Federal Trade Commission antitrust investigation, Reuters reports
- Innovaccer, Mastek ink strategic partnership to scale agentic AI in healthcare globally
- Sandoz strikes $322M biosimilars deal with Shanghai Henlius
- Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indication
- Many Smokers Unaware Of Heart, Brain Risks Of Smoking
- Tylenol, Other Medications Fuel Spike In Liver Damage Cases, Poison Center Data Says
- AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
- My Husband Was Kicked Out Of Hospice For Dying Too Slowly
- Tadalafil (Cialis), Used for BPH and ED, Might Increase Glaucoma Risk, Study Says
- Kennedy’s Quiet Hunt for Autism Culprits Stalls as Trump Orders Baseless Changes to Childhood Shots
- Newsom Promotes Affordable Insulin, but California’s Generic Label Off to a Slow Start
- Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity
- Abridge expands AI decision support to more clinicians in bid to become healthcare's copilot
- Danish politicians call out Eli Lilly obesity campaign
- Universal Health Services closes $835M Talkspace acquisition
- Gounder Brings Clarity to Egg Freezing, AI Virus Creation, and New Trump Vaccine Order
- States Enact Emergency Orders On Kratom While Awaiting Federal Rules
- Study examines how ICHRA adoption could help stabilize ACA risk pools
- Winter Is Coming: How Vaccines Help Protect Against Respiratory Illness
- Screen Time Is Not All Bad For Kids' Brains
- Processed Foods Linked To Prostate Cancer Risk
- Updated Statement Regarding the Division of Corporation Finance’s Role in the Exchange Act Rule 14a-8 Process
- It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
- Industry Voices—AI should help cancer patients survive the healthcare system
- Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
- Sleep Disturbances Linked To Genetic Alzheimer's Risk
- Pre-K Sets Kids Up For School Success, Study Says
- Expect Other Seniors To Act Their Age? Then Expect Problems With Your Own Memory, Study Says
- A genomics library for the AI era
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
- People With Disabilities Say Medicaid Income Limits Stifle Career Advancement
- Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
- My Husband Was Kicked Out of Hospice for Dying Too Slowly
- Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
- Rare Bacteria In Coastal Waters Has Killed 7 This Summer
- It's crunch time for Karyopharm as company faces potential default next month
- Socializing: A Prescription For Healthier Brain Aging
- Taking The Stairs May Lower Your Risk Of Dying From Heart Disease
- AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
- How consumerization is reshaping pharma marketing
- Sweet Tooth? It Could Be Shaping Your Decisions, Study Says
- Stressed Parents Turn To Screens For Help, Study Finds
- Gambling Linked To Mental Health Problems Among College Students
- Hospitals Say They Found A Tool To Help Reduce Childbirth Risks: Wristbands
- Listen to the Latest ‘KFF Health News Minute’
- Readers Speak Out on Work Requirements, Federal Data Grab, Opioid Payback Cash
- People With Disabilities Say Medicaid’s Limits on Income Stifle Career Advancement
- FDA Wants More Information From Food Makers On New Food Chemicals
- Aspirin/Omega-3 Combo Matches Antibiotics In Treating Gum Disease, Trial Finds
- Endometriosis Linked To Higher Type 2 Diabetes Risk
- Beyond Compliance: Rethinking No Surprises Act strategy
- Tamiflu Helps Keep Severely Ill Kids Out Of The ICU, Study Finds
- 'Normal' Can Backfire During Doctor/Patient Discussions
- Experimental Pulse Oximeter Accurate Regardless Of Skin Tone, Researchers Say
- Patients Wary Of Governments, Companies Pushing AI As A Rural Healthcare Solution
- Executive Order Calls For Fewer Routine Childhood Vaccines, Doctors Push Back
- Real-World Performance Of Alzheimer's Drug, Leqembi, Matches Trial Data, Study Finds
- Study Finds Undisclosed Chemicals In Most Personal Care Products
- Chairman Paul S. Atkins Letter to Robert Walley, Chair, CAT NMS Plan Operating Committee
- What 524B and QMSR Change About Medical Device Risk
- Taking Lean Manufacturing to the Next Level
- Why Few MedTech Sales Teams Are Using AI Where It Matters Most
- Why Organizations Miss Emerging Product Risk: Understanding the engineering mechanisms that remain hidden long before complaint trends become visible
- Update on the SEC’s Work Toward Treasury Clearing Implementation [August 2026]
- The Interface is the Risk: A MedTech Blueprint for AI and System Integration
- Restoring Regulatory Clarity: Statement on Technical Amendments to Rule 0‑1(a)(7)
- Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
Michigan healthcare freedom community forum
The breath-taking extent to which health insurance interferes between patient and clinician comes to life in this Associated Press documentary.
Photo library clipped due to length, but remains available at the link.
Limits to anti-nausea pill coverage wear on cancer patients and doctors
Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits.
Doctors say restrictions on the number of tablets patients receive can hurt care. Pharmacy benefit managers say their limits guard against overuse, and they offer workarounds to get more tablets.
In between sit patients, who might ration pills or opt for less effective help for a dreaded side effect of radiation or chemotherapy.
The conflict shows how an array of coverages and poor communication can complicate even simple acts of care in the fragmented U.S. health care system.“This is sort of the dirty underbelly of the current health care environment,” said oncologist Dr. Fumiko Chino. “Insurance companies and pharmacy benefit managers are somehow weirdly ending up in my exam room, standing between me and my patients.”
Steven Manetta takes at least a half dozen pills daily to help keep a form of leukemia in remission. For more than a year, he rationed his go-to anti-nausea pill, ondansetron, known by the brand-name Zofran.
Manetta’s coverage through CVS Caremark paid for 18 ondansetron pills every 21 days. That forced him to sometimes use alternatives that make him extremely drowsy in order to stretch his supply. He only recently got approval for a 90-day supply.
“It’s just like an extra thing to think about all the time,” the 33-year-old Lemont, Illinois, resident said. “When you’re on so many medications, the ones with the least side effects are the ones you always want to reach for.”
Ondansetron hit the U.S. market more than 30 years ago. It was the first in a series of drugs that gave doctors a better way to control nausea and vomiting, said Dr. Alexi Wright, a Dana-Farber Cancer Institute oncologist who teaches at Harvard.
Wright and other cancer specialists call ondansetron a cornerstone treatment because of its relative safety, effectiveness and limited side effects.
The price doesn’t hurt either: Thirty tablets of ondansetron can cost under $12 through prescription discount websites.
Pharmacists and doctors say they’ve dealt with restrictions on anti-nausea drugs like ondansetron for years. Wright says she finds the limits “infuriating” in part because the drug is affordable.
More than half the plans sold on the U.S. individual insurance marketplace limit the number of ondansetron tablets that patients can get, according to preliminary results from a study by Chino and Michael Anne Kyle, a University of Pennsylvania researcher.
Pharmacist Yen Nguyen frequently sees these restrictions, including the limits from CVS Caremark that Manetta encountered.
“Over four or five months of chemotherapy, you’re fighting for dimes and nickels here,” said Nguyen, executive director of pharmacy for the Houston-area practice Oncology Consultants.
Jennette Murphy paid cash for ondansetron when her cancer treatment started earlier this year because she couldn’t get coverage for the amount her doctor requested. Then she got a letter telling her the drug wouldn’t be covered.
“It freaked me out,” the Tehachapi, California, resident said. “I’m like, ‘Really? Have you ever been through chemo?’”
Pharmacy benefit managers say they set limits based partly on the treatment and offer several ways for doctors to request more.
Prime Therapeutics limits 4- and 8-milligram prescriptions of ondansetron to 21 tablets over 30 days. That helps provide “maximum dosing” for seven days of treatment a month, chief clinical officer David Lassen said in an email.
He said quantity limits are approved by independent doctors and pharmacists. They help prevent waste and excessive use that may not be safe.
CVS Caremark spokesman Mike DeAngelis said his company bases limits on Food and Drug Administration guidelines. He added that the company can make a decision on requests for more tablets in less than 24 hours.
Doctors say they don’t always know when patients will need more.
Coverage limits vary, and some patients may not tell their doctor that they got a smaller-than-desired amount. Also, nausea intensity can be hard to gauge with newer treatments.
Chino says she wants patients to start with 90 tablets of ondansetron, enough to take the drug three times a day for a month if needed. But she often sees limits of 21 or 30 tablets.
“The fact that there’s still restrictive patterns on this very useful medication is insane,” said Chino, who recently moved from Memorial Sloan Kettering in New York to MD Anderson in Houston.
Limits can hurt patients who have big copayments for each refill or trouble getting to the drugstore, noted Dr. Ramy Sedhom, an oncologist and palliative care specialist with Penn Medicine Princeton Health.
“I have a lot of patients who only go to the pharmacy once a month when their niece or nephew is in town to pick up the (prescriptions),” he said.
If patients run out of ondansetron, even for a few days, uncontrolled vomiting can send them to emergency rooms or force a treatment pause, doctors say.
Murphy, the cancer patient, has avoided all of that. She said coverage started for ondansetron after her City of Hope cancer center doctor requested it.
She faces a stretch of chemotherapy cycles that will extend well into the fall. The treatments leave her bedridden for days with nausea even while taking ondansetron.
“I would hate to not have it,” she said.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.























